Member Info for bobbyaxelrod

How does this compare to Thruvision?

Is it just for me that their website is non-functional?

This company is so undervalued with so many strings to its bow. Good proposition with just the music, never mind TCAT and M&M

I still think this represents a good acquisition target for a larger company like Hipgnosis or Round Hill given the small market cap, solid balance sheet with cash and multiple offerings. Impressed they are continuing to add to their catalogue and think they are taking a careful approach to purchasing rights only where it makes business sense.

I do agree with a previous poster that their website could use some work - last time I checked it seemed messy.

The increased retail sales will hopefully drive, not just a recovery, but a boost to hospitality and travel retail sales. I hope they don't sell brands off but instead build them. With domestic sales growing 60% and exports 200% it does not seem like they are demand constrained.

2021 should bring lots more sales: weddings, parties, celebrations, nights out, travel, hotels, etc. I hope they are well placed to capitalise.

If this keeps dropping I will add more.

- Will use bank facility to fund business provided lockdowns end before April 2021
- Likely to be able to work with bank to a workable agreement
- Possible governmental additional support
- Continuation of existing support: business rates holidays, VAT deferrals
- End of H1 they had 32mn net cash
- Worries regarding rights issue (I don't know what will happen). I think this would only happen if pushed by lenders or lockdowns extend. It's unknown how much they would want to raise and whether this would even be worth it. At around 350mn shares there would be significant dilution £50mn would be about 125mn more shares. Given they have such a large facility to use, that they don't anticipate having to fully utilise, it would seem easier and cheaper to use the facility. Once trading resumes this business generates solid cash flows which it can use to manage debt and reinvest for online offering.

"Whilst our short term cash requirement can be covered within our existing £200m bank facility, we anticipate that current covenants will be breached at the end of January as the significant impact of the November and current national lockdowns are reflected in our trading performance. We continue to have constructive discussions with our banking syndicate.

Despite the unprecedented nature of this year, our aggressive but considered management of costs and cash has resulted in a material reduction in our utilisation of the debt facility, resulting in net debt being reduced to £90m as at 31 December 2020, compared to the net debt of £119m as at 31 December 2019. We would not expect this facility to be fully utilised unless the national lockdown, restricting non-essential retailers from trading, continues beyond the end of April 2021.

Despite initially being given access to Coronavirus Corporate Finance Facility (CCFF), following changes to the scheme rules, we no longer have that opportunity. We are, however, progressing discussions to access supplemental funding options."

Great RNS. Slowly ticking away under the radar. Great balance sheet, well run business.

42 market cap, PE 13, growing revenues and profits, growing dividend with good cover. Fantastically well-run organisation.

Adopting a Buffet approach, I ask myself would I want to own the entire business, and the answer would be a resounding yes. Took a position here earlier in the year, and expect to see consistent share price and revenue growth for the long term. The revenue drivers do not look like they will be disappearing over the next few decades.

The move into healthcare adds another revenue stream that the market isn't valuing due to these not being long term contracts. But it is unlikely that these contracts will not continue at their current levels minimum, whilst the rest of the business is growing.

Brands are doing well, global ambitions, great team, possible acquisitions (but only if they are fairly valued and add value), growing investment into digital.

I can't help thinking this represents could value and reads as a very well run business. In the October trading update they say no dividend reinstatement until 24/25. What do you more seasoned investors in this stock think of this?

The whole thing reads more like political posturing, for instance mentioning the business rates situation. They have around 1.5 cover historically for their dividend and payout most of their earnings possibly related to BoD owning 65% of the company.

As the share price drops, my interest rises.

What made you sell? I'm interest to hear a different perspective.

My rationale:
I've added more during dips. I think the acquisition is good and allows them to move Ireland (maybe enabling faster EU growth) but also includes a few different services. Overall the business is well run with dividends, and strong balance sheet. The revenue drivers, which all result in an increasing disparity between radiological demands and radiologist supply, are still there.

I think Medica share price reflected eventual UK domination, something a la Rightmove, but sitting at (last time I checked) 50% of UK trusts with the new Ireland acquisitions, means all that UK growth is still available at a minimum. I think they might be able to manage any margin pressure through higher volumes and additional services.

But I have felt inpatient with the share price at times.

Bought this at 6p, happily watched it all the way to 12.5p and all the way back down to where we are now.

The technology is promising and useful. It lends itself well to a royalty model. The main factor here is the tiny market cap, which as we have seen can explode.

I think next time I’d be tempted to take a bit off, rather than waiting for the 2nd coming of novacyt

On all websites their products have the highest reviews - says it all!

Reading this forum has made me feel shameful for taking profits. Still have a small holding that I can hopefully watch go to the moon, but was feeling uneasy with having significant unrealised paper profits that could remain unrealised.

At this moment in time it is wise to mine valuable cryptocurrencies, but if bitcoin isn't adopted by governments what happens then - bitcoin will continue nonetheless whilst governments still will require their own digital currencies. When I first read through Argo's admission documents I had the initial idea that Argo could mines on demand for banks, UK governments and so on - what do people think about the feasibility of this happening?

Was really interested in this business that does important work.

But put off by admission paperwork showing current liabilities exceeding current assets, loss-making, and Root Capital (I think) owning c50% of the business whilst also lending it a loan at 8% pa that has been consistently rolled over despite being classed as a trade payable (payment falling within 1 year).

Feels like the raise via IPO might be masking these problems, simply fulfilling the purpose of giving Root Capital its return and keep the business treading water in the hope it can be profitable with scale, which is a shame - but I am probably completely wrong

Especially compared to its peers it's undervalued. The 5+% dividend is great, especially considering the demand drivers (e.g. old ageing population) and pipeline. I haven't mentioned the likelihood of being a key player in the covid vaccine scene, as the CEO explained they are simply not the first but does not mean they won't be a major player. For instance their partnership with Vir is aiming towards producing a more effective, potent vaccine that is resistant to any virus mutation - this seems like a good approach for long term value. Their adjuncts are likely to be key for any other vaccines made as well as their own.

Their pipeline is strong with heavy focus on infectious diseases and cancer, and I think as R&D spend comes to fruition the share price will re-rates in anticipation of growth. And all this plays out with the safety of a solid dividend.

GSK know what they are doing - I am still not convinced the consumer healthcare company spin out will be any good its own but time will tell.

My average is 1391.60, and my aim is to use the dividend in this to invest elsewhere or reinvest in GSK if it remains undervalued.

Have been slowly accumulating a position here for the long term - think we will see stable dividend and slow growth with eventual re-rating. If anyone has a spare hour then the most recent earnings call seems very positive. GSK seems to have a such a strong pipeline coming to fruition over the next few years. Whenever the market faces an inevitable sell-off at some point maybe next year defensive GSK should hold.

It seems re. the spin-off: they are in no rush to split the consumer healthcare company, and they want to do this without incurring significant additional costs, instead funding through divestments and debt. I think that GSK will come out of the split stronger, having used the profits to fund its R&D for its next growth phase. I am not sure how good of an asset shares in the consumer healthcare company - might even be better to self this off straightaway rather than list separately, but 2 for 1 offer always nice.

Award Winning/

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, is pleased to announce that it has won the AIM Transaction of the Year.

In June 2020, Inspiration Healthcare announced the acquisition of S.L.E. Limited for a consideration of £18.0 million which was raised by way of a Placing and Open Offer to certain institutional and individual investors by Cenkos Securities. S.L.E. is a leader in the design and manufacture of ventilators and capital equipment for neonatal intensive care, treating premature and sick babies. S.L.E.'s products are sold across the world through a distribution network built over many years.

More news/

nspiration Healthcare Group plc (AIM: IHC), the global medical technology company, is pleased to announce that "Project WAVE" has been granted a patent by the European Patent Office and can now be validated in individual countries within the EU.

"Project WAVE" is a novel technology used in a respiratory device for neonatal intensive care which was acquired under licence by Inspiration Healthcare in 2019 from a major US West Coast University. The project has been granted a patent by the US Patent Office which was announced on 25 March 2020.

On 16th November 2020 it was announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has cleared project WAVE for clinical testing which is expected to commence in the new year at the Trevor Mann Baby Unit, Brighton & Sussex University Hospital (Royal Sussex).

Neil Campbell, Chief Executive Officer, commented: "As we continue to move forward in the development of Project WAVE this is another milestone passed and one which both protects our IP and the investment we have made to ensure that this technology soon becomes adopted in hospitals, and we remain confident that once this happens, we will begin to see improved medical outcomes using this novel technology."

Little movement in this so far - apart from down. They have cash, pay a dividend and have multiple offering. Think it's good value for such a small market cap.

With many strings to their bow like TCAT (wonder how proprietary this is, although do they say that the largest music distributors are customers for this) and very small market cap, could see this multibagging over time or being acquired by one of the larger song funds (hipgnosis / round hill).

Looks like a tasty uptrend, hopefully I've not jinxed it.

The company is well-run with a clear strategy to achieve growth. Cash rich, profitable enough to commence a dividend, and market cap only around £50mn. Hopefully they can make well priced acquisitions.

Even though the P/E is around 20, it could easily achieve growth, not just in earnings, but in its earnings multiple.